Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 12,548 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined therapy treatment Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Low-intensity Resistance Exercise and Diet on Arterial Function and Blood Pressure

NCT01371370
View directory record Official record
Conditions
Obesity, Pre-hypertension, Hypertension
Interventions
Resistance exercise training, Hypocaloric diet, Resistance exercise training & diet
Other
Lead sponsor
Florida State University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 31, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Restorative Early Sleep Treatment After the Emergency Department

NCT07121270
View directory record Official record
Conditions
Insomnia, Nightmares Associated With Trauma and Stress, Nightmares, PTSD - Post Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia and Nightmares, Sleep Education, Sleep Education enhanced with Nightmare Education
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

NCT02544451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 31, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

NCT02153229
View directory record Official record
Conditions
Epitheliod Malignant Pleural Mesothelioma
Interventions
Photodynamic Therapy, Radical Pleurectomy, Chemotherapy, Photofrin 2.0 mg/kg
Radiation · Procedure · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

NCT00031629
View directory record Official record
Conditions
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim
Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

NCT00001045
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
57
States / cities
Los Angeles, California • San Francisco, California • San Jose, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 10:27 PM EDT
Active, not recruiting Phase 1 Interventional

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

NCT04891757
View directory record Official record
Conditions
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Interventions
FHD-286, Low Dose Cytarabine, Decitabine
Drug
Lead sponsor
Foghorn Therapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 31, 2026, 10:27 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

NCT07535112
View directory record Official record
Conditions
Advanced/Metastatic Colorectal Adenocarcinoma
Interventions
BAY 3771249, Cetuximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Duarte, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

NCT00084981
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
decitabine, valproic acid, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 31, 2026, 10:27 PM EDT
Completed No phase listed Observational

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

NCT00507442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

NCT01783756
View directory record Official record
Conditions
Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
lapatinib ditosylate, everolimus, capecitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 31, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222
View directory record Official record
Conditions
Lymphoma
Interventions
Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Telephone-Delivered Exercise for Multiple Sclerosis Fatigue

NCT03256851
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Physical Activity
Interventions
Telephone-Delivered Exercise Therapy, In-Person Delivered Exercise Therapy
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 31, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Masitinib, Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Galesburg, Illinois • Bethesda, Maryland • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

NCT01476839
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab
Biological · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075
View directory record Official record
Conditions
Advanced Cancer
Interventions
AB801, Docetaxel
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

NCT02008565
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Loperamide, Placebo, Anal exercises with biofeedback, Usual Care
Drug · Behavioral
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 31, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Herceptin, Carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 31, 2026, 10:27 PM EDT